Research programme: monoclonal antibody therapeutics - Integral molecular
Latest Information Update: 24 Nov 2016
At a glance
- Originator Integral Molecular
- Class Monoclonal antibodies
- Mechanism of Action GLUT4 stimulants; Immunomodulators; Membrane protein modulators; Purinergic P2X3 receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Chikungunya virus infections; Ebola virus infections; Neuropathic pain; Type 2 diabetes mellitus; Zika virus infection